Sign in
4

Changes in Ownership

IONIS PHARMACEUTICALS INC Filed Acc 0000874015-23-000241

Director sold 117,638 shares at an average $50.48 ($5,938,129)

  • Director acquired 117,638 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

PARSHALL B LYNNE · Director

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2023-12-26 Exercise or conversion : show line 1 in the form 10b5-1 +25,113 $47.34 $1,188,849 107,701 D
2023-12-26 Sale : show line 2 in the form 10b5-1 −25,113 $51.46 $1,292,390 82,588 D
2023-12-27 Exercise or conversion : show line 3 in the form 10b5-1 +50,000 $47.34 $2,367,000 132,588 D
2023-12-27 Sale : show line 4 in the form 10b5-1 −50,000 $50.23 $2,511,515 82,588 D
2023-12-28 Exercise or conversion : show line 5 in the form 10b5-1 +42,525 $47.34 $2,013,134 125,113 D
2023-12-28 Sale : show line 6 in the form 10b5-1 −42,525 $50.19 $2,134,223 82,588 D
Open-market sales · 117,638 sh · avg $50.48 · $5,938,129

Table II: Derivative

3 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2023-12-26 Exercise or conversion : show line 7 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −25,113 $47.34 2024-01-02 25,113 92,525 D
2023-12-27 Exercise or conversion : show line 8 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −50,000 $47.34 2024-01-02 50,000 42,525 D
2023-12-28 Exercise or conversion : show line 9 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −42,525 $47.34 2024-01-02 42,525 0 D
Loading xslF345X05/edgardoc.xml…